House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 144 Tuesday, February 21, 2017 11:00 a.m. |
|
|
|
|
Introduction of Government Bills |
|
Introduction of Private Members' Bills |
|
Notices of Motions (Routine Proceedings) |
|
Questions |
|
| Q-8832 — February 17, 2017 — Mr. Eglinski (Yellowhead) — With regard to the February 16, 2017, band election conducted by the O’Chiese First Nation: (a) when did the Minister of Indigenous and Northern Affairs approve the application by the band to change its election rules; (b) why did the Minister of Indigenous and Northern Affairs approve the change; (c) what specific rules were changed; (d) is the Minister of Indigenous and Northern Affairs aware of allegations that individuals were refused the right to run in the election as a result of decisions made by the Chief and Council that were based on a previous bias; (e) what reasons was the Minister of Indigenous and Northern Affairs provided with regarding why certain individuals were refused the right to run for office; (f) does the Minister of Indigenous and Northern Affairs consider the reasons provided in (e) to be valid; and (g) what specific requirements has the Minister of Indigenous and Northern Affairs put in place to ensure that the O’Chiese First Nations conducts elections in a transparent and legal manner? |
| Q-8842 — February 17, 2017 — Mr. MacKenzie (Oxford) — With regard to materials prepared regarding Bill S-201, An Act to prohibit and prevent genetic discrimination: for every briefing document prepared, (i) what is the date on the document, (ii) who was the sender, (iii) who was the recipient, (iv) what is the title or subject matter of the document, (v) what is the department’s internal tracking number? |
| Q-8852 — February 17, 2017 — Mr. Richards (Banff—Airdrie) — With regard to the rules used to define active versus passive income for purposes of the small business deduction: (a) when was the review of the rules, which was originally started in Budget 2015, completed and if the review was not completed (i) when did the government decide to discontinue the review, (ii) what were the reasons for the discontinuation of the review; (b) prior to the discontinuation or completion of the review in (a), were any consultations or analyses undertaken by the Minister of National Revenue or the Minister of Finance and, if so, what were (i) the results, (ii) the date of each consultation, (iii) the location of each consultation, (iv) the name and title of individuals or groups consulted, (v) the recommendations that were made to the Ministers; (c) when was the decision made to change the interpretation of rules, which was issued through a bulletin by the Canada Revenue Agency on August 23, 2016, and by whom was the decision made; (d) prior to the issue of the bulletin in (c), were any consultations or analyses undertaken by the Minister of National Revenue or the Minister of Finance; and (e) if the answer to (d) is in the affirmative, what were (i) the results, (ii) the date of each consultation, (iii) the location of each consultation, (iv) the name and title of individuals or groups consulted, (v) the recommendations that were made to the Ministers? |
| Q-8862 — February 17, 2017 — Mr. Brassard (Barrie—Innisfil) — With regard to the use of mefloquine by members of the Canadian Armed Forces as an anti-malaria drug as directed by the Minister of National Defence: (a) how many Canadian Armed Forces members have been given mefloquine annually in each of the years since mefloquine was first used by the Canadian Armed Forces in 1993; (b) what other anti-malaria drugs has the Canadian Armed Forces administered to forces members; (c) what year did the Canadian Armed Forces change the use of mefloquine from mandatory to optional for Canadian Armed Forces members; (d) how many members of the Canadian Armed Forces have been returned to Canada from deployment for not taking or refusing mefloquine; and (e) how many Canadian Armed Forces members were refused deployment to a mission for refusing to take mefloquine? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
Government Business |
|
Private Members' Notices of Motions |
|
Private Members' Business |
| M-105 — December 2, 2016 — Ms. Sgro (Humber River—Black Creek) — That, in light of the death of over 1000 Canadians each year, including the tragic loss of the Honourable Mauril Bélanger, former MP for Ottawa—Vanier on August 16, 2016, as a consequence of Amyotrophic Lateral Sclerosis (ALS), the House: (a) reiterate its desire and commitment to, in collaboration with provincial and territorial stakeholders, combat ALS via research and awareness; and (b) call upon the government to increase funding for ALS research, and to substantially increase national efforts to develop and launch a comprehensive strategy to assist with the eradication of ALS at the earliest opportunity. |
|
|
|
| 2 Response requested within 45 days |
|